Novo Nordisk and Eli Lilly rival soars 35% after promising weight loss drug results

Shares of Denmark's Zealand Pharma rose 35% on Monday after results showed success in its liver disease treatment survodutide, which is also on trial as a drug to treat obesity.

The Phase 2 trial of the survodutide drug showed 83% of adults saw positive results for a form of liver inflammation caused by excess fat cells known as "MASH," the company said in an announcement Monday. Analysts latched onto the drug's possible efficacity in obesity research after the latest test results, which indicated the safety of the top dosage used in that trial.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Gene therapy at CHOP allowed a deaf boy to hear. But some deaf people object to the treatment.A second deaf patient is undergoing the treatment, produced by Eli Lilly, at CHOP on Friday.
Source: PhillyDailyNews - 🏆 89. / 67 Read more »

Novo Nordisk settles two lawsuits over copycat versions of Ozempic and WegovyBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »